Showing results (1-10 of 81) with videos related to

Sort By:
Pageof 9
International Journal of Inflammation|February 23, 2013
Gab docking proteins in cardiovascular disease, cancer, and inflammationYoshikazu Nakaoka, Issei Komuro
Circulation Journal : Official Journal of the Japanese Circulation Society|December 20, 2023
Current Immunosuppressive Treatment for Takayasu ArteritisYoh Arita, Tomohiko Ishibashi, Yoshikazu Nakaoka
JACC. Case Reports|July 28, 2021
Perioperative Management of Takayasu Arteritis for Cardiac Surgery in a Patient Treated With TocilizumabYoh Arita, Yoshikazu Nakaoka, Yuko Eda, et al.
Cell Reports|May 24, 2018
Myocardial Angiopoietin-1 Controls Atrial Chamber Morphogenesis by Spatiotemporal Degradation of Cardiac JellyKyun Hoo Kim, Yoshikazu Nakaoka, Hellmut G Augustin, et al.
Modern Rheumatology|July 31, 2023
A multicentre, large-scale, observational study of tocilizumab in patients with giant cell arteritis in JapanMasayoshi Harigai, Takako Miyamae, Hideyuki Hashimoto, et al.
Circulation Journal : Official Journal of the Japanese Circulation Society|September 4, 2020
Current Trends in Epidemiology and Clinical Features of Thromboangiitis Obliterans in Japan　- A Nationwide Survey Using the Medical Support System DatabaseYoshiko Watanabe, Tetsuro Miyata, Kunihiro Shigematsu, et al.
Biomed Research International|June 20, 2015
Gab1 Is Modulated by Chronic Hypoxia in Children with Cyanotic Congenital Heart Defect and Its Overexpression Reduces Apoptosis in Rat Neonatal CardiomyocytesMyriam Cherif, Massimo Caputo, Yoshikazu Nakaoka, et al.
Circulation Research|August 27, 2005
Enhanced functional gap junction neoformation by protein kinase A-dependent and Epac-dependent signals downstream of cAMP in cardiac myocytesSatoshi Somekawa, Shigetomo Fukuhara, Yoshikazu Nakaoka, et al.
Modern Rheumatology|September 3, 2022
A multicentre, large-scale, observational study of tocilizumab in patients with Takayasu arteritis in Japan: The ACTEMRA® (ACT)-Bridge studyMasayoshi Harigai, Takako Miyamae, Hideyuki Hashimoto, et al.
Rheumatology Advances in Practice|March 19, 2025
Phase 3, multicentre, randomized, double-blind, placebo-controlled, parallel-group study of ustekinumab in patients with Takayasu arteritisHajime Yoshifuji, Tomonori Ishii, Hiroki Ohashi, et al.
Pageof 9